Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial; Administrative Supplement
症状前家族性 ALS (Pre-fALS) 研究 - 治疗试验的前奏;
基本信息
- 批准号:10363844
- 负责人:
- 金额:$ 17.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-15 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdministrative SupplementAmyotrophic Lateral SclerosisAntisense OligonucleotidesBiologicalBiological MarkersC9ORF72ClinicalComplexDNA Sequence AlterationDataDiagnosisDiseaseEarly intervention trialsElementsEnrollmentEventFutureGene MutationGenesGenetic CounselingGenetic RiskGleanGrantHandIndividualInfrastructureInvestigational TherapiesKnowledgeMethodsMotor NeuronsNatural HistoryNeurodegenerative DisordersPersonsPhasePopulationPopulations at RiskPreparationPrevention trialProceduresProcessRiskSymptomsTherapeuticTherapeutic AgentsTherapeutic InterventionTimebasecohortdesigndisorder preventionfamilial amyotrophic lateral sclerosisfollow-upgenetic testinginsightmultimodalitypreventive interventionscreeningsuccesssuperoxide dismutase 1therapeutic candidatetherapeutic developmenttherapy developmenttreatment trialtrial design
项目摘要
PROJECT SUMMARY
A major challenge to therapy development efforts in the field of ALS is the relatively late stage in the course of
the disease at which treatment is initiated. While the reasons for this are complex, one critically important
factor is that the disease process almost certainly begins well before the earliest clinical manifestations of
disease with significant loss of motor neurons by the time of symptom onset, and even more so by the time of
diagnosis (which is typically made about a year after symptom onset). We have long championed the idea that
an early therapeutic, or even a preventative, trial would offer much greater likelihood of success and could be
undertaken in people at risk for ALS. In contemplating such a trial, however, we recognized that too little was
known about the pre-symptomatic phase of ALS, including elements critical to trial design. This prompted us to
initiate (in 2007) Pre-fALS (Pre-Symptomatic Familial ALS), a longitudinal natural history and biomarker study
of pre-symptomatic individuals who are carriers of an ALS-associated gene mutation; they are currently the
only known population at risk for ALS and in whom a study of pre-symptomatic disease may be considered.
Over the course of the last 10 years, we have developed and refined methods for screening and enrolling
individuals who may be at risk for developing ALS; providing pre-symptomatic genetic counseling and testing;
and maintaining longitudinal follow-up with minimal loss to follow-up. In so doing, we have gradually expanded
the Pre-fALS cohort to include 113 gene-positive individuals and have accumulated a total of ~447 person-
years follow-up; 14 of these individuals have progressed to clinically manifest disease, yielding an estimated
average two-year phenoconversion rate of ~10%. With significant preliminary data in hand and the operational
infrastructure now in place, we are poised to expand the Pre-fALS cohort, significantly extend cumulative
follow-up time and can expect to observe a total of ~45 phenoconversion events by the end of the grant cycle.
Employing a multi-modal array of evaluative procedures that includes both ‘wet’ and ‘dry’ biomarkers which
permit quantification of subclinical signs of disease, we will address two very specific questions that are
fundamental to the design of a future disease prevention trial. First, we will determine whether it is possible to
identify a subset of people at genetic risk for ALS who are at a sufficiently high-short term risk of developing
disease that a reduction in risk could be used to adequately power a disease prevention trial. Second, we will
quantify longitudinal trajectories of pre-symptomatic biomarkers to determine whether changes in these
biomarkers could be used to quantify the biological impact of an experimental therapeutic in a disease
prevention trial. These data and the insights we glean into the pre-symptomatic stage of disease, will enable us
to design and implement a disease prevention or early intervention trial in the near future that could utilize
whatever therapeutic agent(s) hold the most promise at the time we are ready to initiate a groundbreaking trial
of this sort. SOD1 and C9orf72 antisense oligonucleotides are likely early experimental therapeutic candidates.
项目概要
ALS 领域的治疗开发工作面临的一个主要挑战是治疗过程中相对较晚的阶段。
开始治疗的疾病。虽然造成这种情况的原因很复杂,但其中一个至关重要
因素是,疾病过程几乎肯定早在最早的临床表现出现之前就开始了。
在症状出现时运动神经元明显丧失的疾病,在症状出现时更是如此
诊断(通常在症状出现一年左右进行)。我们长期以来一直倡导这样的想法:
早期的治疗甚至预防性试验将提供更大的成功可能性,并且可能
在有 ALS 风险的人群中进行。然而,在考虑进行这样的试验时,我们认识到,我们所做的努力太少了。
了解 ALS 症状前阶段,包括对试验设计至关重要的要素。这促使我们
启动(2007 年)Pre-fALS(症状前家族性 ALS),一项纵向自然史和生物标志物研究
症状前个体是 ALS 相关基因突变的携带者;他们目前是
仅已知有 ALS 风险且可考虑对症状前疾病进行研究的人群。
在过去 10 年中,我们开发并完善了筛选和注册方法
可能有患 ALS 风险的个人;提供症状前遗传咨询和检测;
保持纵向随访,将随访损失降到最低。在此过程中,我们逐渐扩大了
Pre-fALS 队列包括 113 名基因阳性个体,总计约 447 人
年随访;其中 14 人已发展为临床表现出的疾病,估计
平均两年表型转化率约为 10%。掌握了重要的初步数据和可操作的
基础设施现已到位,我们准备扩大 Pre-fALS 队列,显着延长累积
随访时间,预计在资助周期结束时观察到总共约 45 个表型转化事件。
采用多模式评估程序,包括“湿”和“干”生物标志物,
为了允许量化疾病的亚临床症状,我们将解决两个非常具体的问题:
对未来疾病预防试验的设计至关重要。首先我们要确定是否可以
确定具有 ALS 遗传风险的一小部分人,他们的短期发展风险足够高
疾病风险的降低可以用来充分推动疾病预防试验。其次,我们将
量化症状前生物标志物的纵向轨迹,以确定这些变化是否
生物标志物可用于量化实验疗法对疾病的生物学影响
预防试验。这些数据和我们收集到的疾病症状前阶段的见解将使我们能够
在不久的将来设计和实施疾病预防或早期干预试验,可以利用
当我们准备好启动突破性试验时,无论哪种治疗剂最有希望
这类的。 SOD1 和 C9orf72 反义寡核苷酸可能是早期实验性治疗候选药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Benatar其他文献
Michael Benatar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Benatar', 18)}}的其他基金
Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)
多中心 ALS 生物标志物验证研究 (CReATe Biomarkers)
- 批准号:
10410344 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
University of Miami NeuroNEXT Trial Site
迈阿密大学 NeuroNEXT 试验网站
- 批准号:
10201771 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)
多中心 ALS 生物标志物验证研究 (CReATe Biomarkers)
- 批准号:
10612967 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
University of Miami NeuroNEXT Trial Site
迈阿密大学 NeuroNEXT 试验网站
- 批准号:
10593638 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
University of Miami NeuroNEXT Trial Site
迈阿密大学 NeuroNEXT 试验网站
- 批准号:
9980517 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial
症状前家族性 ALS (Pre-fALS) 研究 - 治疗试验的前奏
- 批准号:
10237152 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
Clinical Centers for the NINDS NeuroNEXT(Network of Excellence in Neuroscience Clinical Trials) Consortium
NINDS NeuroNEXT(神经科学临床试验卓越网络)联盟的临床中心
- 批准号:
10744345 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial
症状前家族性 ALS (Pre-fALS) 研究 - 治疗试验的前奏
- 批准号:
10469619 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial
症状前家族性 ALS (Pre-fALS) 研究 - 治疗试验的前奏
- 批准号:
10001608 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)
多中心 ALS 生物标志物验证研究 (CReATe Biomarkers)
- 批准号:
9923007 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
相似海外基金
Proton-secreting epithelial cells as key modulators of epididymal mucosal immunity - Administrative Supplement
质子分泌上皮细胞作为附睾粘膜免疫的关键调节剂 - 行政补充
- 批准号:
10833895 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement)
无家可归者使用芬太尼兴奋剂多物质的纵向定性研究(行政补充)
- 批准号:
10841820 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
StrokeNet Administrative Supplement for the Funding Extension
StrokeNet 资助延期行政补充文件
- 批准号:
10850135 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
- 批准号:
10896844 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
Biomarkers of Disease in Alcoholic Hepatitis Administrative Supplement
酒精性肝炎行政补充剂中疾病的生物标志物
- 批准号:
10840220 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
Administrative Supplement: Life-Space and Activity Digital Markers for Detection of Cognitive Decline in Community-Dwelling Older Adults: The RAMS Study
行政补充:用于检测社区老年人认知衰退的生活空间和活动数字标记:RAMS 研究
- 批准号:
10844667 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
Administrative Supplement: Improving Inference of Genetic Architecture and Selection with African Genomes
行政补充:利用非洲基因组改进遗传结构的推断和选择
- 批准号:
10891050 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
Power-Up Study Administrative Supplement to Promote Diversity
促进多元化的 Power-Up 研究行政补充
- 批准号:
10711717 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
Administrative Supplement for Peer-Delivered and Technology-Assisted Integrated Illness Management and Recovery
同行交付和技术辅助的综合疾病管理和康复的行政补充
- 批准号:
10811292 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
Administrative Supplement: Genome Resources for Model Amphibians
行政补充:模型两栖动物基因组资源
- 批准号:
10806365 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:














{{item.name}}会员




